Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility)

Slides:



Advertisements
Similar presentations
Planning Collaborative Spaces in Libraries
Advertisements

Presented to: CCSSO 2012 National Conference on Student Assessment June 27, 2012 Quality Assurance in a Chaotic World An External Perspective.
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Common/shared responsibilities between jobs.
Background This linked collaborative is intended to identify opportunities to exchange best practices, administrative and regulatory support models and.
Module 11: Community TB Care Image source: Pierre Virot, World Lung Foundation.
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic)
Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.
Southeast florida’s regional vision for economic prosperity experts teamworkoutreach the blueprint.
PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.
Sudan Community Development Fund: Preliminary Slice I Impact Evaluation Results and Needs for Future Evaluations Abdulgadir Turkawi, Krishna Pidatala,
EVIDENCE BASED HEALTH CARE and BEST PRACTICES at Northwestern Health Sciences University Gert Bronfort DC, PhD; Michele Maiers, DC, MPH; Roni Evans DC,
Elements of a clinical trial research protocol
Conceptual, Methodological and Practical Issues in the Recruitment and Retention of Participants OBSSR’s NIH Summer Institute on Behavioral and Social.
Coordinating Center Overview November 18, 2010 SPECIAL DIABETES PROGRAM FOR INDIANS Healthy Heart Project Initiative: Year 1 Meeting 1.
Coordinating Center Overview November 16, 2010 SPECIAL DIABETES PROGRAM FOR INDIANS Diabetes Prevention Program Initiative: Year 1 Meeting 1.
Center for Health Care Quality Licensing & Certification Program Evaluation 1 August 2014 rev.
1a Job Descriptions for Personnel Involved in PAT Implementation Materials Developed by The IRIS Center, University of Maryland.
CAHPS Overview Clinician & Group Surveys: Practical Options for Implementation and Use AHRQ ANNUAL MEETING SEPTEMBER 18, 2011 Christine Crofton, PhD CAHPS.
Pilot Study Design Issues
Evaluating NSF Programs
1-2 Training of Process FacilitatorsTraining of Coordinators 5-1.
Revenue Cycle Management Medical Technology Acquisition and Assessment Team Members: Joseph Dixon, Michael Morotti, Mari Pirie-St. Pierre, David Robbins.
Protocol Complexity as a Factor in Vendor Management Compliance Risk
Solution Overview for NIPDEC- CDAP July 15, 2005.
Use of OCAN in Crisis Intervention Webinar October, 2014.
NCI-sponsored treatment trials: CTCAE v4 790 individual items Standard Approach to AE Monitoring CATEGORYEXAMPLEDATA SOURCE LaboratoryNeutropeniaLaboratory.
PRO-CTCAE Task 8 Committee: Feasibility Research March 18 th 2011 (11am EST) Kickoff Telecon.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Conducting a Study Safely and Efficiently at Johns Hopkins Daniel E Ford, MD, MPH Vice Dean for Clinical Investigation July 20, 2010.
Software Quality Assurance Activities
CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.
American Association for the Treatment of Opioid Dependence, Inc National Conference, Atlanta April 25, 2006 Evaluation of the Impact of Opioid Treatment.
Connecting South Carolina: The Gibbs/Hollings Cancer Center An NCCCP/NCI Designated Center Connection Anita L. Harrison, MPH Associate Director, Administration.
S1316 – The Malignant Bowel Obstruction Study Forms and Procedures Katie Arnold, MS SWOG Statistical Center Seattle, WA 10/24/2014S1316 Training1.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Amy P. Abernethy, MD Task 6: Usability.
2011 ACRIN Annual Meeting The ACRIN Accrual Project at University of Washington Constance Lehman, MD. PhD David Mankoff, MD. PhD Tiffany Wong, MS.
University of Idaho Successful External Program Review Archie George, Director Institutional Research and Assessment Jane Baillargeon, Assistant Director.
September 12, 2004 Simplifying the Administration of HIPAA Security Angel Hoffman, RN, MSN Director, Corporate Compliance University of Pittsburgh Medical.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Evidence-Based Medicine Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department of.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2014.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Brightening Oral Health: Teaching and Implementing Oral Health Risk Assessments in Pediatric Care QuIIN Members Multiple studies document that the development.
Assessment and Management of Depression, Anxiety, and Alcohol Problems in Primary Care: The BHL Program VISN 4 MIRECC VA Philadelphia University of Pennsylvania.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Systems Accreditation Berkeley County School District School Facilitator Training October 7, 2014 Dr. Rodney Thompson Superintendent.
Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.
Sandra A. Mitchell, PhD, CRNP Outcomes Research Branch, DCCPS
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.
Systems Analysis & Design AUTHOR: PROFESSOR SUSAN FUSCHETTO 10/24/
Building a Research Core Road Map and Lessons Learned Scott A. LeMaire, MD Professor of Surgery and of Molecular Physiology and Biophysics Vice Chair for.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
1 Community-Based Care Readiness Assessment and Peer Review Overview Department of Children and Families And Florida Mental Health Institute.
Unit 8: Implementation, Part II Seminar Wednesday pm ET.
No Conflicts of Interest Including the Patient Voice in Safety Reporting Ethan Basch, MD, MSc Health Outcomes Group Departments of Medicine and Epidemiology/Biostatistics.
Medidata Rave Start-Up Information
Clinical Project Meeting NYHQ PPS Delivery System Reform Incentive Payment (DSRIP) Project Implementation Plan Development Asthma (3dii)
CHB Conference 2007 Planning for and Promoting Healthy Communities Roles and Responsibilities of Community Health Boards Presented by Carla Anglehart Director,
PRAGMATIC Study Designs: Elderly Cancer Trials
Responsibilities of Sponsor, Investigator and Monitor
CLINICAL PROTOCOL DEVELOPMENT
Pre-implementation Processes Implementation, Adoption, and Utility of Family History in Diverse Care Settings Study Lori A. Orlando, MD MHS.
Description of Revision
Clinical Trial Development: RA’s Role, OEWG, and IRB Submissions Martha Heckel Protocol Associate, ACRIN Dept. of Protocol Development & Regulatory.
{Project Name} Organizational Chart, Roles and Responsibilities
Presentation transcript:

Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility) Committee October 5, 2011

Outline 1.Background 2.Rationale 3.Data sources: Correlative studies in cooperative group clinical trials – Approach to measuring feasibility – Approach to measuring cost

PRO-CTCAE Background Contract I ( ) + ARRA ( ) – Items developed Cognitive interviewing complete Validation study 90% complete – Web software developed Usability testing conducted to revise software

PRO-CTCAE Background Contract II ( ) – Expand accessibility to patients Develop IVRS Spanish translation and linguistic validation – Determine optimal approach to clinician and patient AE reporting in cancer clinical trials – Assess feasibility and cost of implementation in cooperative group clinical trials

Rationale for Assessing Feasibility/Cost Towards future, need to understand feasibility and cost of implementing PRO-CTCAE in clinical trials at: – NCI level, Group level, Site/staff level (CRA and investigator), patient level – Including level of acceptance/enthusiasm at each level; barriers/effective strategies and infrastructure, effort, cost Can inform modifications of approach, strategic decisions, resource allocation

Data Source: Correlative Studies in 2 Clinical Trials RTOG 1012 (Manuka honey) – Randomized phase II symptom intervention trial – Primary outcome: Improvement of esophagitis-related pain during RT for lung cancer – PRO-CTCAE completed weekly by iPad in clinic, with backup data collection methods – Status: Activation 10/19/11 Alliance/NCCTG 1048 (rectal cancer) – Phase II/III trial – Hypothesis: neoadjuvant FOLFOX and restaging can risk stratify patients to selectively avoid combined modality therapy (CMT) before low anterior resection (LAR) with similar outcomes to CMT + LAR – PRO-CTCAE completed weekly by IVRS from home, with backup data collection methods – Status: CTEP review

Additional Studies Outside of Contract PRO-CTCAE is being integrated into several Alliance and RTOG trials as an exploratory endpoint by enthusiastic investigators Material Transfer Agreement (MTA) mechanism developed – Permitting investigator-initiated research – Supporting R01 and R21 applications

What Do We Mean By Feasibility and Cost? Feasibility – Willingness and ability of stakeholders/entities at each level to integrate PRO-CTCAE into trials Cost – Resources required at each level to implement PRO-CTCAE, including personnel effort, equipment, services

Measuring Feasibility: NCI Level System hosting – Logistics, technical difficulties, troubleshooting – Descriptive approach

Measuring Feasibility: Group Level Descriptive approach – Willingness to integrate into trials Leadership Clinical committees/Study Chairs Concept review committees – Feasibility of integrating into protocols Investigators Protocol editors Statisticians Preliminary – Highly feasible, increasing interest to use PRO-CTCAE – Reflected in survey

Feasibility: Site/Staff Level Staff feedback survey/semi-structured interviews Training and central coordination – Ability to centrally train and coordinate staff – Ability to train patients Patient enrollment – Proportion of eligible patients enrolled – Reasons for non-enrollment Technical issues – Also assessed in usability and validation studies Logistical barriers and recommendations SEE ATTACHED SURVEYS

Feasibility: Patient Level Proportion of patients willing to participate – Reasons for non-participation – Associated patient characteristics Proportion of enrolled patients using the system at each time point – Reasons for non-adherence – Associated patient characteristics

Cost Diagram COST Site Level Cooperative Group Level NCI Level Hosting Web IVRS Operations and maintenance Technical support System super admin System improvements Hosting Web IVRS Operations and maintenance Technical support System super admin System improvements Pre-study Develop protocol sections Develop forms During study Centralized teaching Monitoring QA Post-study (statistical) Data cleaning Statistical analysis Pre-study Develop protocol sections Develop forms During study Centralized teaching Monitoring QA Post-study (statistical) Data cleaning Statistical analysis CRAs Teach patients Monitor compliance Reminders/backup data collection Investigators/clinicians Address alerts CRAs Teach patients Monitor compliance Reminders/backup data collection Investigators/clinicians Address alerts

NCI-Level Costs Software system hosting, operations and maintenance – Obtain from CBIIT – Note: these are ongoing costs (i.e., not per-study)

Group Level (Per Trial) Administrative – Will estimate from feasibility trials, other trials, discussion with group leadership – In feasibility studies, providing % of site per-patient reimbursement – likely not required for standard use Alliance: 54% IDC RTOG: 27% IDC Central coordination – 20% effort of study coordinator a central coordinating site Statistical – Estimate from Alliance/Mayo statistical Center: $ /trial (includes analyst and statistician)

Site Level Plan for estimating cost in feasibility trials Based on measuring self-reported effort of CRAs and investigators/clinicians Developed by Committee including NCI and external methodological experts 1.CRA questionnaire (administered at 6-months) Learn system, teach patients, monitor, remind 2.CRA semi-structured interviews Follow-up on questionnaire, what could expedite 3.Investigator/clinician questionnaire Review patient reports SEE ATTACHED SURVEYS

Excerpts from CRA Survey How many hours of training did it take for you to learn how to use the PRO-CTCAE software system? (ask # and range) On average, how many minutes does it take you to train a patient to use the PRO-CTCAE software system? On average, how many minutes does it take you to train a patient? At each follow up visit, how much time do you spend with patients to assist them…? For each patient… on average how much time do you spend between visits addressing issues related to the PRO-CTCAE (helping patient with passwords, addressing automated alerts, etc)?

Discussion Points Adequacy of planned approaches – Feasibility at group level – Cost at site level Other potential approaches Future – Role of PRO-CTCAE data in study monitoring (DSMB) – Approach to AE data analysis and reporting – Regulatory role